Ambrosia lands $16m to ‘improve on existing GLP-1 drugs’

Biotech startup Ambrosia Biosciences has emerged with a $16 million Series A financing to develop new treatments for obesity and metabolic disorders. While information on the company’s approach is limited, its initial plan is to “discover and develop novel orally delivered, small molecule-based therapies targeting incretins and other class B GPCRs.”